An additional option in secondary stroke prevention
What Changed
On November 9, 2026, the FDA announced approval of asundexian (Sunharbo), a factor XIa inhibitor used alongside antiplatelet therapy for adults after a recent non-cardioembolic ischemic stroke (NIHSS ≤15) or high-risk TIA. In OCEANIC-STROKE, 12,327 adults were randomized. Over a median treatment duration of 14.2 months, the FDA reported a 26% relative reduction in ischemic stroke compared with placebo, with antiplatelet therapy in both groups. This is a relative reduction, not a 26-percentage-point absolute difference.
Who It Affects
Stroke teams, pharmacists, formulary committees and clinicians caring for potentially eligible secondary-prevention patients. This does not establish an indication for atrial-fibrillation stroke prevention.
Why It Matters
The approval adds a treatment option, but generalizing the efficacy estimate beyond studied eligibility is inappropriate. Overall major bleeding rates were similar. The FDA reported increased major bleeding in patients older than 75 and during the first 90 days, as well as more gastrointestinal bleeding with asundexian. The FDA announcement is a regulatory summary, not a substitute for full trial data or prescribing information.
Original Sources
The 2027 Medicare physician fee schedule changes the math
What Changed
CMS released its CY 2027 Medicare Physician Fee Schedule final rule, generally effective January 1, 2027. The projected conversion factors are $32.95 for qualifying APM participants and $32.63 for nonqualifying participants, decreases of 1.83% and 2.31%, respectively, from 2026.
Who It Affects
Physician practice administrators, revenue-cycle leads and clinicians responsible for service-line planning.
Why It Matters
A conversion factor is one input in payment, not an across-the-board forecast of practice revenue. Procedure mix, relative value units, geography and adjustment rules can alter actual effects.
Original Sources
Editorial notes & disclaimers
Editorial note: The Context Edit provides general, source-backed news analysis and education as of the date published. It is not individualized professional advice. Information may change; consult current primary sources and qualified professionals before making consequential decisions.
Healthcare: This briefing is not medical advice, diagnosis, treatment guidance or a substitute for clinical judgment. Review current prescribing information, clinical guidance and patient-specific risks before clinical use.
Business & Procurement: This briefing is not legal, regulatory, accounting or procurement advice. Verify applicable law, current agency guidance and solicitation-specific requirements before acting.
